MedCity News August 2, 2024
Frank Vinluan

The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma. It’s the first engineered cell therapy approved for treating a solid tumor.

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory decision that makes the new product the first engineered cell therapy approved for treating a solid tumor.

Known in development as afamitresgene autoleucel, or afami-cel, the new Adaptimmune product will be marketed under the brand name Tecelra.

“Adaptimmune was founded on the conviction that cell therapy would revolutionize the treatment of cancer,” CEO Adrian Rawcliffe said, speaking during a Friday conference call. “This has been...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article